Back

Impact of prolonged use of angiotensin receptor-neprilysin inhibitors versus angiotensin-converting enzyme inhibitors/angiotensin receptor blockers in patients with heart failure reduced ejection frac

20 May 2023 (08:00 - 20:00)
Organised by: Logo
Congress Presentation Part of: Heart failure with reduced ejection fraction (HFrEF) 2 Heart Failure with Reduced Ejection Fraction (HFrEF) HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Bo Eun PARK

Kyungpook National University Hospital, Daegu (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail
The usefulness of end-expiratory oxygen partial pressure as a prognostic indicator in patients with heart failure with reduced ejection fraction
Doctor T. Nakade (Tokyo, JP)
Abstract Slides
Presentation thumbnail
SGLT2 inhibitors in heart failure with reduced ejection fraction without diabetes mellitus: why are patients outside the magic circle?
Doctor D. Santoro (Pavia, IT)
Abstract Slides
Presentation thumbnail
Integrated transcriptomic and regulatory RNA sequencing and machine-learning driven analyses identify molecular signatures underlying human heart failure
Doctor J. Gulia (Bengaluru, IN)
Abstract Slides
Presentation thumbnail
Cardiac amyloidosis patients with reduced ejection fraction have an increase morbimortality
Doctor F. Bauer (Le Kremlin-Bicetre, FR)
Abstract Slides
Presentation thumbnail
Ivabradine improves survival in children with severe chronic heart failure
Doctor R. Adorisio (Rome, IT)
Abstract Slides

Access the full session

Session thumbnail
Heart failure with reduced ejection fraction (HFrEF) 2

The Event

Event poster

Heart Failure 2023

20 May - 23 May 2023
You may be interested in
thumbnail
Congress Presentation
Distinguishing heart failure with reduced ejection fraction from heart failure with preserved ejection fraction: a phenomics approach.
thumbnail
Congress Presentation
Clinical characteristics and long-term prognosis of patients with heart failure with reduced, mildly reduced, and preserved left ventricular ejection fraction secondary to Chagas cardiomyopathy
thumbnail
Webinar
Advanced heart failure therapy in HF patients with preserved and mildly reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources